Previous 10 |
Relay Therapeutics (NASDAQ: RLAY ) : Q2 GAAP EPS of -$6.06 misses by $5.03 . Cash, cash equivalents and investments totaled $312M as of June 30, 2020 $312M Press Release More news on: Relay Therapeutics, Inc., Earnings news and commentary,
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported second quarter 2020 financial results. ...
After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings, China's largest housing platform operating under the Lianjia and Beike brands, plans to raise...
Point Roberts, WA and Delta, BC - July 31, 2020 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor resource announces its weekly roundup of stocks added to its global stock directories, including biotech and mining. This week's new biotech compan...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...